Clinical trial
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of…
NCT00056966 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00056966 |
|---|---|
| Title | Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases |
| Official title | Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancy |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | ANTI-CD45, CAMPATH-1H, FK506, Fludarabine, Total Body Irradiation, Stem cell infusion |
| Enrollment | 24 |
| Start date | Nov 1, 2002 |
| Primary completion | May 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Mar 27, 2003 |
| Last update posted | Jun 29, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: